Journal article
A phase I trial of high-dose paclitaxel, cyclophosphamide and mitoxantrone with autologous blood stem cell support for the treatment of metastatic breast cancer
Abstract
The aim of this phase I study was to determine the dose limiting toxicity (DLT), maximum tolerated dose (MTD) and efficacy of a new combination of cyclophosphamide (6 g/m2), mitoxantrone (70 mg/m2), with dose escalation of paclitaxel (TaxolR) at a starting dose of 250 mg/m2 given intravenously over 3 h in a transplantation setting. Patients with metastatic breast cancer and chemosensitive disease were eligible. The autologous blood stem cell …
Authors
Glück S; Germond C; Lopez P; Cano P; Dorreen M; Koski T; Arnold A; Dulude H; Gallant G
Journal
European Journal of Cancer, Vol. 34, No. 7, pp. 1008–1014
Publisher
Elsevier
Publication Date
June 1998
DOI
10.1016/s0959-8049(97)10168-x
ISSN
0959-8049